GlassScriptPhysician profile
Chandima Ratnayake
NPI 1659696367
$11,314.60
in general payments reported to CMS, 2019-2025
37 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $1,561 · 2021: $4,009 · 2022: $2,017 · 2023: $646 · 2024: $83.30 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $2,155.28 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,769.99 | 2019-2023 | Farxiga |
| Abbvie INC. | $779.50 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.24 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $492.35 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $440.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $432.91 | 2019-2021 | |
| Lilly USA, LLC | $418.41 | 2019-2025 | Kisunla |
| Abbott Laboratories | $306.71 | 2019-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $295.11 | 2019-2023 | Trintellix |
| Novo Nordisk INC | $288.90 | 2020-2021 | |
| Allergan, INC. | $286.31 | 2019-2021 | |
| Nevro Corp. | $266.31 | 2021 | |
| Merck Sharp & Dohme LLC | $253.85 | 2019-2023 | Verquvo, Belsomra |
| Arbor Pharmaceuticals, INC. | $235.30 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $185.52 | 2021-2022 | |
| Pfizer INC. | $182.27 | 2019-2023 | |
| Mannkind Corporation | $178.97 | 2019-2021 | |
| Amarin Pharma, INC. | $175.93 | 2019-2021 | |
| Axsome Therapeutics, INC. | $143.51 | 2023 | Auvelity |
| Amgen INC. | $142.06 | 2019-2023 | Evenity |
| Si-Bone, INC. | $133.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $132.76 | 2019-2021 | |
| Glaxosmithkline, LLC. | $125.39 | 2020-2021 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Medtronic USA, INC. | $118.86 | 2019 | |
| Hologic Sales and Service, LLC | $117.28 | 2019 | |
| Braintree Laboratories, INC. | $90.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $70.65 | 2022 | |
| Nestle Healthcare Nutrition INC. | $50.66 | 2021-2022 | |
| Dexcom, INC. | $43.98 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $40.29 | 2020 | |
| Mylan Specialty L.P. | $18.10 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $17.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.00 | 2021 | |
| Almatica Pharma LLC | $14.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandima Ratnayake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.